CJC-1295 Without DAC
Also known as Modified GRF (1-29), Mod GRF 1-29, Tetrasubstituted GRF (1-29)
A modified 29-amino-acid fragment of growth hormone-releasing hormone, engineered to resist the rapid enzymatic breakdown that limits the native peptide.
Preclinical research
Size
3 options- Catalog no.
- CND2
- Specification
- 2mg*10vials
- Per kit
- 10 vials
For laboratory research use only. Not for human or animal consumption. Buyers must be 21 or older.
Overview
CJC-1295 without DAC, often called modified GRF (1-29), is a synthetic analogue of the first 29 amino acids of human GHRH, the shortest fragment that keeps full receptor activity. Four amino acid substitutions are introduced to protect the peptide from cleavage by dipeptidyl peptidase-4 and other proteases. Unlike CJC-1295 with DAC, it carries no albumin-binding group, so its action remains short. It is studied as a tool for probing pulsatile growth hormone release from the anterior pituitary.
Class: Growth hormone-releasing hormone (GHRH) analogue
Mechanism of action
How the compound acts, as described in the literature.
Binds the GHRH receptor (GHRH-R) on somatotroph cells of the anterior pituitary, a G protein-coupled receptor that raises intracellular cAMP.
Increased cAMP signaling stimulates synthesis and pulsatile release of growth hormone, which in turn drives hepatic IGF-1 production.
Substitutions at positions 2, 8, 15 and 27 reduce cleavage by dipeptidyl peptidase-4 and improve chemical stability compared with native GRF (1-29).
Because it lacks an albumin-binding moiety, its activity is brief and preserves the episodic pattern of GH secretion.
Published research
Selected studies, each linked to its PubMed record. Summaries describe what the studies reported.
1986
In vitro and in vivo study
PMID 3093533Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus.
Frohman LA, et al. · J Clin Invest
Showed that native GHRH is rapidly cleaved at its N-terminus in plasma, producing an inactive fragment. This instability motivated later stabilized analogues.
1994
Human pharmacokinetic study
PMID 7962295Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men.
Soule S, et al. · J Clin Endocrinol Metab
In healthy men, substituting D-alanine at position 2 of GHRH(1-29) lengthened its half-life and lowered its metabolic clearance compared with the native fragment.
1994
Preclinical study
PMID 7937325Enhanced stability and potency of novel growth hormone-releasing factor (GRF) analogues derived from rodent and human GRF sequences.
Campbell RM, et al. · Peptides
Reported GRF analogues with amino acid substitutions that improved stability and potency, the design approach behind modified GRF (1-29).
Evidence & safety
What the research does not show, and the adverse events and regulatory status it reports.
No published clinical trial has evaluated this tetrasubstituted analogue itself; the evidence comes from studies of native GHRH and of individual substitutions. Like other GHRH analogues it raises GH and IGF-1, and the long-term safety of repeated exposure has not been characterized. It is not approved for any use.
Specifications
All sizes, exactly as catalogued.
| Catalog no. | Product | Specification | Vials per kit |
|---|---|---|---|
| CND2 | CJC-1295 Without DAC | 2mg*10vials | 10 |
| CND5 | CJC-1295 Without DAC | 5mg*10vials | 10 |
| CND10 | CJC-1295 Without DAC | 10mg*10vials | 10 |
For laboratory research use only. Not for human or animal consumption. Not intended to diagnose, treat, cure or prevent any disease. Research summaries are provided for educational purposes and do not describe this product’s use.